Navigation Links
Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
Date:10/25/2007

"We look forward to future research efforts to further elucidate the role of AGEs in gastrointestinal complications including diabetic intestinal dysfunction, diabetic enteropathy and diabetic gastroparesis and the role that alagebrium may play in those disease."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties in
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Lightlake Therapeutics Inc. ("Lightlake") ... based on its expertise in opioid antagonists, announced ... from a prominent international research and development foundation. ... promoting innovative research-based initiatives, including those addressing health ... for the delivery of naloxone that could widely ...
(Date:7/30/2014)...  Hospira, Inc. (NYSE: HSP ), ... infusion technologies, today reported results for the second ... the quarter were $1.1 billion and adjusted* diluted ... specified items as described later in this press ... Generally Accepted Accounting Principles (GAAP) basis, second-quarter 2014 ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
(Date:7/30/2014)... 2014 Nationally recognized leader in nursing ... since September 2013 has served as president of the ... dean of the College of Nursing at University of ... leadership of the NLN, as the nation's premier voice ... nursing and research institutions in the country. , ...
(Date:7/30/2014)... 2014 Within weeks freshman will begin to pour ... hopes this will be a time of growth and the start ... pause; it may not be as easy as it looks. Some ... switch their major at least once and many will switch two ... the costs are exacerbated when switching in the later years of ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Throughout the ... patients with free oral cancer screenings. Using a new ... work to detect the disease in its early stages. ... tongue, cheek, mouth, sinuses, throat and other areas in ... Institute’s Surveillance, Epidemiology, and Ends Results (SEER) program, 30 ...
(Date:7/30/2014)... 2014 Serial entrepreneur, Paul Mata, spent the ... However, like most people, in 2008 he suffered extreme financial ... better way, Paul carefully studied the difference between people who ... not. Based on the knowledge he acquired, he was able ... life and health, but also grow his clients' personal and ...
(Date:7/30/2014)... Thompson HealthDay Reporter WEDNESDAY, ... are more likely to develop dementia, but researchers have been ... the two. Specifically, they haven,t been able to figure ... depression help bring on dementia, or does dementia cause people ... 30 in the journal Neurology sheds more light ...
Breaking Medicine News(10 mins):Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3
... ... is happy to provide his patients with Invisalign clear aligners, a new technology that ... make getting straight teeth easier than ever before. , ... Torrance, California (PRWEB) April 29, 2010 -- ...
... cancers could soon allow researchers to identify groups of ... with angiogenesis-inhibitor drugs, a Spanish team reports. Dr ... reports new findings from an analysis of 135 lung ... Carlos Camps, evaluated the expression of 8 different genes ...
... (found in some foods) may help alleviate the severity ... new research study appearing in the May 2010 print ... ( http://www.jleukbio.org ), differing intestinal bacteria in celiac patients ... manipulating the intestinal microbiota with dietary strategies such as ...
... ... FDA Criticisms—Form 483 Letters—for Temperature, Humidity and other Controlled Environments” , ... (Vocus) April 29, ... Letters—for Temperature, Humidity and other Controlled Environments” is now available from Veriteq ...
... risky but can be beneficial, researchers say , THURSDAY, ... better if they undergo deep brain stimulation surgery in ... One year after having the procedure, patients who underwent ... ability to get around and engage in routine daily ...
... ... saying that seems to ring true according to husbands whose wives have had plastic surgery. ... a look at the transformative journey from the husband,s perspective. , ... Newport Beach, Calif (Vocus) April 29, 2010 -- Dr. ...
Cached Medicine News:Health News:Invisalign Clear Aligners Available at Blue Sky Family Dental by Torrance Dentist, Dr. Robert Mondavi 2Health News:Invisalign Clear Aligners Available at Blue Sky Family Dental by Torrance Dentist, Dr. Robert Mondavi 3Health News:Spanish gene expression data promise targeting of anti-angiogenesis treatment 2Health News:Gut bacteria offer new insights -- and hope -- for people with celiac disease 2Health News:Guide for US FDA-Regulated Organizations Now Available 2Health News:Guide for US FDA-Regulated Organizations Now Available 3Health News:Adding Surgery to Meds May Improve Life With Parkinson's 2Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 2Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 3Health News:Cruise Plastic Surgery Looks at Mommy Makeovers from the Husband's Perspective and Offers Tips 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: